Company intelligence / Profile preview

Genaissance Pharmaceuticals

New Haven, Connecticut, United Statessec.gov ↗

Ownership: Private
Development stage: Commercial

Overview

Genaissance developed a proprietary pharmacogenomic platform to identify genetic markers associated with drug response and adverse effects. Its lead therapeutic program was vilazodone for major depressive disorder, which reached Phase 3 clinical trials. The company also marketed the FAMILION Test, a companion diagnostic for inherited cardiac arrhythmias. It focused on leveraging genetic data to improve patient stratification in clinical trials and enable personalized medicine approaches. The company was acquired by Clinical Data in 2005.

Therapeutic areas: PsychiatryCardiovascular
Modalities: Small moleculeDiagnostic test (companion diagnostic)
Industry: Biotech

Partnerships

Organon/Akzo Nobel – collaboration on pharmacogenomics and companion diagnosticsMultiple top biopharmaceutical companies through technology partnerships

Beyond the preview

Go deeper on Genaissance Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Genaissance Pharmaceuticals.

Explore the full profile